Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Lung cancer, Non small cell lung cancer (NSCLC)
Closed
Phase 3
This trial is looking at durvalumab and domvanalimab for non small cell lung cancer that has grown into surrounding tissues.
It is for people with non small cell lung cancer that:
is
can’t be removed by surgery and
hasn’t got worse following
Recruitment start: 18 February 2022
Recruitment end: 30 June 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Shobhit Baijal
AstraZeneca
Last reviewed: 30 Jul 2026
CRUK internal database number: 18641